

Discovery of an anticoagulant drug candidate targeting ANO6 that improves bleeding safety



CARDIOVASCULAR	Candidate
Product Type	Small molecules
Indication	Anticoagulant
Target	ANO6 (Anoctamin 6)
MoA(Mechanism of Action)	<p>Arterial Thrombosis</p> <ul style="list-style-type: none"> Increase Blood Viscosity Adhere to Vessel Wall Promote Platelet: <ul style="list-style-type: none"> • Margination • Adhesion • Aggregation • Activation <p>Venous Thrombosis</p> <ul style="list-style-type: none"> Increase Blood Viscosity Aggregate Adhere to Vessel Wall Promote Thrombin Generation Increase Thrombus Size Reduce Thrombus: <ul style="list-style-type: none"> • Permeability • Dissolution <p>Legend: RBCs, Fibrin, Bleeding Patch, Activated Platelet, Smooth Muscle Cell, Endothelial Cell, Leukocytes</p> <ul style="list-style-type: none"> ANO6 inhibitors prevent the exposure of phosphatidylserine (PS) on the cell surface by blocking Ca^{2+} - dependent phospholipid scrambling in activated platelets. This reduces the procoagulant activity of platelets without significantly increasing bleeding risk.
Competitiveness	<ul style="list-style-type: none"> • An innovative anticoagulant with a novel mode of action • Shows improved bleeding safety profile compared to conventional drugs
Development Stage	Candidate
Route of Administration	Oral

Any unauthorized distribution or reproduction of this material is strictly prohibited.